查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1631531

呼吸道融合細胞病毒診斷市場規模、佔有率、趨勢分析報告（按產品、最終用途、地區、細分市場預測），2025 年至 2030 年

Respiratory Syncytial Virus Diagnostics Market Size, Share & Trends Analysis Report By Product (DFA, RADT, Molecular Diagnostics, Chromatographic Immunoassay), By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

呼吸道融合細胞病毒診斷市場的成長與趨勢

根據Grand View Research, Inc.的最新報告，全球呼吸道融合細胞病毒診斷市場規模預計到2030年將達到87億美元，2025年至2030年期間的複合年成長率為5.81%。患有呼吸道疾病（包括呼吸道合胞病毒感染）的新生兒數量不斷增加，以及醫療保健提供者對新生兒診斷的支持舉措，預計將成為影響呼吸道合胞病毒診斷市場的主要促進因素。

根據世界衛生組織統計，2014年美國有超過15萬名兒童（5歲及以下）因RSV感染疾病住院，約1.4萬名老年患者死亡。預計這將在預測期內引發對這些疾病的檢測需求。

此外，截至 2014 年，全球出生率為每 1,000 人有 18.7 名新生兒，預計未來七年嬰兒人口將大幅增加。根據統計，估計2014年中國新生兒數量約為1.342億，這些新生兒易受RSV感染疾病且需要診斷，形成了龐大的市場基數。

2010 年，篩檢拯救嬰兒基金會 (SBTS) 與世界傳染病解決方案組織 (WSAID)夥伴關係，推動新生兒感染疾病、代謝性和聽力障礙的篩檢。

呼吸道融合細胞病毒診斷市場報告重點

  • 層析法免疫檢測比分子診斷具有更高的特異性，在市場佔有率為 27.38%。市售的檢測套組包括 Binax Now RSV、QuickLab RSV Test、Remel Xpect 和 RSV Respi-Strip。
  • 醫院部門將在 2024 年佔據 41.09% 的市場佔有率，佔據市場主導地位，預計在預測期內將以最快的速度成長。預計未來七年內患者對居家照護診斷設備的需求不斷成長將推動該領域的成長。
  • 預計北美將佔據市場主導地位，到 2024 年收益佔有率將超過 41.18%。預計，隨著民眾意識的增強，開始並實施新生兒篩檢，以及世界衛生組織、泛美衛生組織和世界愛滋病規劃署等政府機構的積極努力，將推動這一成長。
  • 市場的主要企業包括諾華公司、雅培公司、BD 公司、Ortho Clinical Diagnostics、羅氏診斷公司、雅培實驗室和賽默飛世爾科技公司。在預計預測期內，CLIA 批准以及羅氏診斷公司、碧迪公司和 Alere Inc. 等公司推出的 RSV 檢測將推動市場成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章呼吸道融合細胞病毒診斷市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 呼吸道融合細胞病毒診斷市場分析工具
    • 產業分析 – 波特五力分析
    • PESTEL 分析

第 4 章呼吸道融合細胞病毒診斷市場：按產品分類的估計和趨勢分析

  • 全球呼吸道融合細胞病毒診斷市場：產品儀表板
  • 全球呼吸道融合細胞病毒診斷市場：產品變異分析
  • 全球呼吸道融合細胞病毒診斷市場（按產品、按收益）
  • 直接螢光抗體測定（DFA）
  • 快速抗原診斷檢測 (RADT)
  • 分子診斷
  • 層析法免疫檢測
    • 重力驅動測試
    • 層析法（OC）
  • 診斷影像
  • 凝膠微滴法
  • 流式細胞技術
  • 其他

第 5 章呼吸道融合細胞病毒診斷市場：按最終用途的估計和趨勢分析

  • 全球呼吸道融合細胞病毒診斷市場：最終用途儀表板
  • 全球呼吸道融合細胞病毒診斷市場：最終用途變異分析
  • 全球呼吸道融合細胞病毒診斷市場（依最終用途和收益）
  • 醫院
  • 實驗室
  • 診所
  • 其他

第6章呼吸道融合細胞病毒診斷市場：依產品、最終用途、區域、估計和趨勢分析

  • 區域控制面板
  • 市場規模、預測趨勢分析，2018-2030
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 主要市場參與企業的近期趨勢及影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • 主要經銷商及通路夥伴名單
    • 2024 年主要企業的市場佔有率分析
    • BD（Becton, Dickinson, and Company）
    • Novartis AG
    • Abbott
    • QuidelOrtho Corporation
    • Thermo Fisher Scientific Inc.
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd.
    • BIOMERIEUX
    • DiaSorin SpA
    • Merck KGaA
    • Coris BioConcept
    • Siemens Healthineers AG
    • Quest Diagnostics Incorporated
Product Code: 978-1-68038-680-6

Respiratory Syncytial Virus Diagnostics Market Growth & Trends:

The global respiratory syncytial virus diagnostics market size is estimated to reach USD 8.70 billion by 2030, expanding at a CAGR of 5.81% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing neonatal population suffering from respiratory conditions including RSV infections and supportive initiatives for diagnosis of newborns by the healthcare providers are expected to be vital impact rendering drivers for RSV diagnostics market.

According to the statistics provided by the WHO, hospitalization of over 150,000 children (below the age of five) and about 14,000 deaths in geriatric patients occurred in the U.S. in 2014 due to RSV infections. This is anticipated to trigger demand for testing of these conditions over the forecast period.

Furthermore, the global birth rate as of 2014 is 18.7 births per 1,000 individuals, which is predicted to increase the infant population substantially over the next seven years. According to the statistics, it is estimated that about 134.2 million births took place in 2014, which are prone to RSV infections and require diagnosis, thus forming a large market base.

In 2010, Save Babies Through Screening Foundation (SBTS) entered in a partnership with World Solutions Against Infectious Disease (WSAID) as an attempt to promote higher screening of newborns for infectious diseases, metabolic disorders, and hearing disabilities.

Respiratory Syncytial Virus Diagnostics Market Report Highlights:

  • Chromatographic immunoassay segment dominated the market with a share of 27.38% in 2024 over the next seven years owing to their higher specificity than molecular diagnostic products. The commercially available test kits include Binax Now RSV, QuickLab RSV Test, Remel Xpect, and RSV Respi-Strip.
  • Hospitals segment dominated the market with a share of 41.09% in 2024 and is anticipated to grow at fastest growth rate over the forecast period. Increasing demand for home care diagnostic devices by patients is anticipated to drive growth of the segment over the next seven years.
  • North America is anticipated to dominate the market and contribute a revenue share of over 41.18% by 2024. Rising awareness among the population base and favorable initiatives by the government agencies such as the WHO, PAHO, and WSAID to initiate and implement newborn screening are expected to drive growth.
  • Key players of the market include Novartis AG, Abbott, BD and Company, Ortho Clinical Diagnostics, Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific Inc. CLIA waiver and launch of RSV assays by companies like Roche Diagnostics, Becton Dickinson and Company, and Alere Inc. are expected to boost market growth over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. End use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and End use outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Respiratory Syncytial Virus Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of Respiratory Syncytial Virus (RSV) Infections
      • 3.2.1.2. Advancements in diagnostics technologies
      • 3.2.1.3. Growing awareness and healthcare spending
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost associated with advanced diagnostic tests
      • 3.2.2.2. Lack of awareness in developing reagions
  • 3.3. Respiratory Syncytial Virus Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Social landscape
      • 3.3.2.5. Environmental landscape

Chapter 4. Respiratory Syncytial Virus Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Global Respiratory Syncytial Virus Diagnostics Market: Product Dashboard
  • 4.2. Global Respiratory Syncytial Virus Diagnostics Market: Product Movement Analysis
  • 4.3. Global Respiratory Syncytial Virus Diagnostics Market by Product , Revenue
  • 4.4. Direct Fluorescent Antibody (DFA) Method
  • 4.5. Rapid Antigen Diagnostic Test (RADTs)
    • 4.5.1. Rapid Antigen Diagnostic Test (RADTs) market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.6. Molecular Diagnostics
    • 4.6.1. Molecular diagnostics market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.7. Chromatographic Immunoassay
    • 4.7.1. Chromatography immunoassay market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.7.2. Gravity Driven Test
      • 4.7.2.1. Gravity driven test market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.7.3. Oligochromatography (OC)
      • 4.7.3.1. Oligochromatography (OC) market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.8. Diagnostic Imaging
    • 4.8.1. Diagnostic imaging market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.9. Gel Microdroplets
    • 4.9.1. Gel microdroplets market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.10. Flow Cytometry
    • 4.10.1. Flow cytometry market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.11. Others
    • 4.11.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Respiratory Syncytial Virus Diagnostics Market: End use Estimates & Trend Analysis

  • 5.1. Global Respiratory Syncytial Virus Diagnostics Market: End use Dashboard
  • 5.2. Global Respiratory Syncytial Virus Diagnostics Market: End use Movement Analysis
  • 5.3. Global Respiratory Syncytial Virus Diagnostics Market by End use, Revenue
  • 5.4. Hospitals
    • 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.5. Laboratory
    • 5.5.1. Laboratory market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6. Clinics
    • 5.6.1. Clinics market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Respiratory Syncytial Virus Diagnostics Market: Regional Estimates & Trend Analysis by Type, Tube Material, Application, and End use

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
    • 7.3.4. BD (Becton, Dickinson, and Company)
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Novartis AG
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Abbott
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. QuidelOrtho Corporation
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Thermo Fisher Scientific Inc.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Bio-Rad Laboratories, Inc.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. F. Hoffmann-La Roche Ltd.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. BIOMERIEUX
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. DiaSorin S.p.A.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Merck KGaA
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. Coris BioConcept
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Product benchmarking
      • 7.3.14.4. Strategic initiatives
    • 7.3.15. Siemens Healthineers AG
      • 7.3.15.1. Company overview
      • 7.3.15.2. Financial performance
      • 7.3.15.3. Product benchmarking
      • 7.3.15.4. Strategic initiatives
    • 7.3.16. Quest Diagnostics Incorporated
      • 7.3.16.1. Company overview
      • 7.3.16.2. Financial performance
      • 7.3.16.3. Product benchmarking
      • 7.3.16.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 4 Global Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 5 Global Oncology Companion Diagnostic, by Region, 2018 - 2030 (USD Billion)
  • Table 6 North America Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Billion)
  • Table 7 North America Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 8 North America Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 9 U.S. Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 10 U.S. Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 11 Canada Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 12 Canada Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 13 Mexico Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 14 Mexico Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 15 Europe Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Billion)
  • Table 16 Europe Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 17 Europe Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 18 Germany Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 19 Germany Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 20 UK Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 21 UK Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 22 France Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 23 France Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 24 Italy Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 25 Italy Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 26 Spain Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 27 Spain Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 28 Denmark Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 29 Denmark Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 30 Sweden Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 31 Sweden Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 32 Norway Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 33 Norway Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 34 Asia Pacific Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Billion)
  • Table 35 Asia Pacific Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 36 Asia Pacific Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 37 China Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 38 China Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 39 Japan Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 40 Japan Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 41 India Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 42 India Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 43 South Korea Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 44 South Korea Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 45 Australia Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 46 Australia Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 47 Thailand Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 48 Thailand Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 49 Latin America Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Billion)
  • Table 50 Latin America Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 51 Latin America Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 52 Brazil Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 53 Brazil Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 54 Argentina Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 55 Argentina Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 56 Middle East & Africa Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Billion)
  • Table 57 Middle East & Africa Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 58 Middle East & Africa Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 59 South Africa Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 60 South Africa Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 61 Saudi Arabia Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 62 Saudi Arabia Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 63 UAE Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 64 UAE Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
  • Table 65 Kuwait Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
  • Table 66 Kuwait Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Respiratory Syncytial Virus Diagnostics Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Global Respiratory Syncytial Virus Diagnostics Market: Product Movement Analysis
  • Fig. 16 Global Respiratory Syncytial Virus Diagnostics Market, for Direct Fluorescent Antibody (DFA) Method, 2018 - 2030 (USD Billion)
  • Fig. 17 Global Respiratory Syncytial Virus Diagnostics Market, for Rapid Antigen Diagnostic Test (RADT), 2018 - 2030 (USD Billion)
  • Fig. 18 Global Respiratory Syncytial Virus Diagnostics Market, for Molecular Diagnostics, 2018 - 2030 (USD Billion)
  • Fig. 19 Global Respiratory Syncytial Virus Diagnostics Market, for Diagnostic Imaging, 2018 - 2030 (USD Billion)
  • Fig. 20 Global Respiratory Syncytial Virus Diagnostics Market, for Gel Microdroplets, 2018 - 2030 (USD Billion)
  • Fig. 21 Global Respiratory Syncytial Virus Diagnostics Market, for Flow Cytometry, 2018 - 2030 (USD Billion)
  • Fig. 22 Global Respiratory Syncytial Virus Diagnostics Market, for Others, 2018 - 2030 (USD Billion)
  • Fig. 23 Global Respiratory Syncytial Virus Diagnostics Market: End use Movement Analysis
  • Fig. 24 Global Respiratory Syncytial Virus Diagnostics Market, for Hospitals, 2018 - 2030 (USD Billion)
  • Fig. 25 Global Respiratory Syncytial Virus Diagnostics Market, for Laboratory, 2018 - 2030 (USD Billion)
  • Fig. 26 Global Respiratory Syncytial Virus Diagnostics Market, for Clinics, 2018 - 2030 (USD Billion)
  • Fig. 27 Global Respiratory Syncytial Virus Diagnostics Market, for Others, 2018 - 2030 (USD Billion)
  • Fig. 28 Regional Marketplace: Key Takeaways
  • Fig. 29 Regional Outlook, 2024 & 2030
  • Fig. 30 Global Respiratory Syncytial Virus Diagnostics Market: Region Movement Analysis
  • Fig. 31 North America Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 32 U.S. Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 33 Canada Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 34 Mexico Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 35 Europe Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 36 Germany Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 37 UK Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 38 France Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 39 Italy Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 40 Spain Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 41 Denmark Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 42 Sweden Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 43 Norway Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 44 Asia Pacific Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 45 Japan Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 46 China Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 47 India Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 48 Australia Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 49 South Korea Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 50 Thailand Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 51 Latin America Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 52 Brazil Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 53 Argentina Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 54 Middle East and Africa Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 55 South Africa Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 56 Saudi Arabia Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 57 UAE Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
  • Fig. 58 Kuwait Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)